In vitro discordance with in vivo activity: Humanized exposures of ceftazidime-avibactam, aztreonam, and tigecycline alone and in combination against New Delhi metallo-β-lactamase-producing Klebsiella pneumoniae in a murine lung infection model

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 7, 2017, Pages

  Monogue, M L ^a   Abbo, L M ^b,c   Rosa, R ^c   Camargo, J F ^b   Martinez, O ^b   Bonomo, R A ^d,e   Nicolau, D P ^a  

^a HARTFORD HOSPITAL   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c University of Miami Jackson Memorial Medical Center   (United States)

^d LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^e CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Ceftazidime avibactam; Klebsiella pneumoniae; New Delhi metallo lactamase; Resistance

Indexed keywords

AMIKACIN; AVIBACTAM PLUS CEFTAZIDIME; AZTREONAM; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; COLISTIN; ERTAPENEM; IMIPENEM; MEROPENEM; TIGECYCLINE; TOBRAMYCIN; ANTIINFECTIVE AGENT; AVIBACTAM, CEFTAZIDIME DRUG COMBINATION; AZABICYCLO DERIVATIVE; BETA LACTAMASE INHIBITOR; AVIBACTAM; BETA LACTAMASE CTX M; ISOFLURANE; METALLO BETA LACTAMASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG POTENTIATION; EPSILOMETER TEST; FEMALE; IN VITRO STUDY; IN VIVO STUDY; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; LUNG INFECTION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NEW DELHI METALLO BETA LACTAMASE PRODUCING KLEBSIELLA PNEUMONIAE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; DRUG EFFECTS; ENTEROBACTERIACEAE; KLEBSIELLA INFECTION; MICROBIAL SENSITIVITY TEST; ANTIBACTERIAL ACTIVITY; COMPARATIVE STUDY; DRUG EXPOSURE; FRACTIONAL INHIBITORY CONCENTRATION; MOUSE MODEL; PATHOGENESIS;

ANIMALS; ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; AZTREONAM; BETA-LACTAMASE INHIBITORS; CEFTAZIDIME; ENTEROBACTERIACEAE; FEMALE; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICE; MICROBIAL SENSITIVITY TESTS;

EID: 85021922893     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00486-17.     Document Type: Article

References (15)

1. Queenan AM, Bush K. 2007. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev 20:440–448. https://doi.org/10.1128/CMR.00001-07.
2. Nordmann P, Naas T, Poirel L. 2011. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 17:1791–1798. https://doi.org/10.3201/eid1710.110655.
3. Lagacé-Wiens PR, Tailor F, Simner P, DeCorby M, Karlowsky JA, Walkty A, Hoban DJ, Zhanel GG. 2011. Activity of NXL104 in combination with beta-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum beta-lactamases and class C beta-lactamases. Antimicrob Agents Chemother 55:2434–2437. https://doi.org/10.1128/AAC.01722-10.
4. MacVane SH, Crandon JL, Nichols WW, Nicolau DP. 2014. Unexpected in vivo activity of ceftazidime alone and in combination with avibactam against New Delhi metallo-β-lactamase-producing Enterobacteriaceae in a murine thigh infection model. Antimicrob Agents Chemother 58:7007–7009. https://doi.org/10.1128/AAC.02662-14.
5. Livermore D, Mushtaq S, Warner M, Zhang J, Maharjan S, Doumith M, Woodford N. 2011. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother 55:390–394. https://doi.org/10.1128/AAC.00756-10.
6. Tessier PR, Nicolau DP. 2013. Tigecycline displays in vivo bactericidal activity against extended-spectrum-β-lactamase-producing Enterobacteriaceae after 72-hour exposure period. Antimicrob Agents Chemother 57:640–642. https://doi.org/10.1128/AAC.01824-12.
7. Crandon JL, Nicolau DP. 2013. Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging Gram-negative organisms, including metallo-β-lactamase producers. Antimicrob Agents Chemother 57:3299–3306. https://doi.org/10.1128/AAC.01989-12.
8. Crandon JL, Schuck VJ, Banevicius MA, Beaudoin ME, Nichols WW, Tanudra MA, Nicolau DP. 2012. Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosa. Antimicrob Agents Chemother 56:6137–6146. https://doi.org/10.1128/AAC.00851-12.
9. Rosa R, Rudin SD, Rojas LJ, Perez-Cardona A, Aragon L, Nicolau DP, Perez F, Bonomo RA, Martinez O, Camargo J, Abbo L. 2016. Application of “precision medicine” through the molecular characterization of extensively drug resistant (XDR) Klebsiella pneumoniae in a multivisceral transplant candidate. Open Forum Infect Dis 3(Suppl 1):2032. https://doi.org/10.1093/ofid/ofw172.1580.
10. Clinical and Laboratory Standards Institute. 2016. Performance standards for antimicrobial susceptibility testing; 25th informational supplement. Document 132 M100-S25. Clinical and Laboratory Standards Institute, Wayne, PA.
11. Hall MJ, Middleton RF, Westmacott D. 1983. The fractional inhibitory concentration (FIC) index as a measure of synergy. J Antimicrob Chemother 11:427–433. https://doi.org/10.1093/jac/11.5.427.
12. Gunderson B, Ibrahim KH, Hovde LB, Fromm TL, Reed MD, Rotschafer JC. 2003. Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 47:905–909. https://doi.org/10.1128/AAC.47.3.905-909.2003.
13. Marshall S, Hujer AM, Rojas LJ, Papp-Wallace KM, Humphries RM, Spellberg B, Hujer KM, Marshall EK, Rudin SD, Perez F, Wilson BM, Wasserman RB, Chikowski L, Paterson DL, Vila AJ, van Duin D, Kreiswirth BN, Chambers HF, Fowler VG, Jr, Jacobs MR, Pulse ME, Weiss WJ, Bonomo RA. 2017. Can ceftazidime/avibactam and aztreonam overcome β-lactam resistance conferred by metallo-β-lactamases in Enterobacteriaceae? Antimicrob Agents Chemother 61:e02243-16. https://doi.org/10.1128/AAC.02243-16.
14. Chemaly RF, Hanmod SS, Jiang Y, Rathod DB, Mulanovich V, Adachi JA, Rolston KV, Raad II, Hachem RY. 2009. Tigecycline use in cancer patients with serious infections: a report on 110 cases from a single institution. Medicine (Baltimore) 88:211–220. https://doi.org/10.1097/MD.0b013e3181af01fc.
15. Koomanachai P, Crandon JL, Banevicius MA, Peng L, Nicolau DP. 2009. Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model. Antimicrob Agents Chemother 53:5060–5063. https://doi.org/10.1128/AAC.00985-09.